# Prokidney Corp.: financial statements, quarterly

PROK · Nasdaq · CIK 1850270 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/prok.md) · [Financials](/companies/prok/financials.md) · [Filings](/companies/prok/filings.md) · [Insiders](/companies/prok/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/prok/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0000950170-25-069251.md) | [0.0](/filings/0000950170-25-107352.md) | [0.0](/filings/0001193125-25-274303.md) | [0.1 d](/filings/0001193125-26-113881.md) | [0.2](/filings/0001193125-26-225841.md) | [0.2](/filings/0001193125-26-342373.md) | [0.2](/filings/0001193125-25-274303.md) | [0.2 d](/filings/0001193125-26-113881.md) | [0.2](/filings/0001193125-26-225841.md) | [0.2](/filings/0001193125-26-342373.md) |
| Research and development | $m | [32.2](/filings/0000950170-24-125312.md) | [22.5 d](/filings/0001193125-26-113881.md) | [27.2](/filings/0000950170-25-069251.md) | [29.4](/filings/0000950170-25-107352.md) | [31.3](/filings/0001193125-25-274303.md) | [39.8 d](/filings/0001193125-26-113881.md) | [27.3](/filings/0001193125-26-225841.md) | [25.9](/filings/0001193125-26-342373.md) | [26.8](/filings/0001193125-25-274303.md) | [34.2 d](/filings/0001193125-26-113881.md) | [33.8](/filings/0001193125-26-225841.md) | [36.1](/filings/0001193125-26-342373.md) |
| Operating income | $m | [(46.6)](/filings/0000950170-24-125312.md) | [(24.2) d](/filings/0001193125-26-113881.md) | [(40.1)](/filings/0000950170-25-069251.md) | [(43.1)](/filings/0000950170-25-107352.md) | [(49.0)](/filings/0001193125-25-274303.md) | [(51.6) d](/filings/0001193125-26-113881.md) | [(41.4)](/filings/0001193125-26-225841.md) | [(39.7)](/filings/0001193125-26-342373.md) | [(38.5)](/filings/0001193125-25-274303.md) | [(45.4) d](/filings/0001193125-26-113881.md) | [(44.9)](/filings/0001193125-26-225841.md) | [(48.4)](/filings/0001193125-26-342373.md) |
| Interest expense | $m | [0.0](/filings/0000950170-24-125312.md) | [0.0 d](/filings/0001193125-26-113881.md) | [0.0](/filings/0000950170-25-069251.md) | [0.0](/filings/0000950170-25-107352.md) | [0.0](/filings/0001193125-25-274303.md) | [0.0 d](/filings/0001193125-26-113881.md) | [0.0](/filings/0001193125-26-225841.md) | [0.0](/filings/0001193125-26-342373.md) | [0.0](/filings/0001193125-25-274303.md) | [0.0 d](/filings/0001193125-26-113881.md) | [0.0](/filings/0001193125-26-225841.md) | [0.0](/filings/0001193125-26-342373.md) |
| Income tax | $m | [0.9](/filings/0000950170-24-125312.md) | [2.8 d](/filings/0001193125-26-113881.md) | [0.1](/filings/0000950170-25-069251.md) | [(0.1)](/filings/0000950170-25-107352.md) | [(2.3)](/filings/0001193125-25-274303.md) | [1.7 d](/filings/0001193125-26-113881.md) | [0.6](/filings/0001193125-26-225841.md) | [0.8](/filings/0001193125-26-342373.md) | [0.6](/filings/0001193125-25-274303.md) | [(1.6) d](/filings/0001193125-26-113881.md) | [0.0](/filings/0001193125-26-225841.md) | [0.0](/filings/0001193125-26-342373.md) |
| Net income | $m | [(11.0)](/filings/0000950170-24-125312.md) | [(5.7) d](/filings/0001193125-26-113881.md) | [(9.5)](/filings/0000950170-25-069251.md) | [(12.5)](/filings/0000950170-25-107352.md) | [(17.9)](/filings/0001193125-25-274303.md) | [(21.3) d](/filings/0001193125-26-113881.md) | [(16.7)](/filings/0001193125-26-225841.md) | [(16.6)](/filings/0001193125-26-342373.md) | [(16.5)](/filings/0001193125-25-274303.md) | [(19.2) d](/filings/0001193125-26-113881.md) | [(20.0)](/filings/0001193125-26-225841.md) | [(28.4)](/filings/0001193125-26-342373.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [191](/filings/0000950170-23-063688.md) | [60.6](/filings/0000950170-25-040483.md) | [84.4](/filings/0000950170-24-057785.md) | [215](/filings/0000950170-24-094732.md) | [108](/filings/0000950170-24-125312.md) | [99.1](/filings/0001193125-26-113881.md) | [97.8](/filings/0000950170-25-069251.md) | [84.9](/filings/0000950170-25-107352.md) | [95.3](/filings/0001193125-25-274303.md) | [109](/filings/0001193125-26-342373.md) | [102](/filings/0001193125-26-225841.md) | [74.9](/filings/0001193125-26-342373.md) |
| Current assets | $m | [406](/filings/0000950170-23-063688.md) | [374](/filings/0000950170-25-040483.md) | [340](/filings/0000950170-24-057785.md) | [450](/filings/0000950170-24-094732.md) | [430](/filings/0000950170-24-125312.md) | [396](/filings/0001193125-26-113881.md) | [360](/filings/0000950170-25-069251.md) | [324](/filings/0000950170-25-107352.md) | [300](/filings/0001193125-25-274303.md) | [281](/filings/0001193125-26-342373.md) | [235](/filings/0001193125-26-225841.md) | [190](/filings/0001193125-26-342373.md) |
| Total assets | $m | [452](/filings/0000950170-23-063688.md) | [421](/filings/0000950170-25-040483.md) | [388](/filings/0000950170-24-057785.md) | [499](/filings/0000950170-24-094732.md) | [475](/filings/0000950170-24-125312.md) | [441](/filings/0001193125-26-113881.md) | [406](/filings/0000950170-25-069251.md) | [372](/filings/0000950170-25-107352.md) | [352](/filings/0001193125-25-274303.md) | [336](/filings/0001193125-26-342373.md) | [293](/filings/0001193125-26-225841.md) | [249](/filings/0001193125-26-342373.md) |
| Current liabilities | $m | [21.0](/filings/0000950170-23-063688.md) | [25.0](/filings/0000950170-25-040483.md) | [19.3](/filings/0000950170-24-057785.md) | [20.6](/filings/0000950170-24-094732.md) | [25.2](/filings/0000950170-24-125312.md) | [36.2](/filings/0001193125-26-113881.md) | [32.8](/filings/0000950170-25-069251.md) | [28.3](/filings/0000950170-25-107352.md) | [29.1](/filings/0001193125-25-274303.md) | [30.7](/filings/0001193125-26-342373.md) | [25.9](/filings/0001193125-26-225841.md) | [22.7](/filings/0001193125-26-342373.md) |
| Total liabilities | $m | [23.6](/filings/0000950170-23-063688.md) | [29.2](/filings/0000950170-25-040483.md) | [24.7](/filings/0000950170-24-057785.md) | [26.8](/filings/0000950170-24-094732.md) | [31.3](/filings/0000950170-24-125312.md) | [39.4](/filings/0001193125-26-113881.md) | [36.1](/filings/0000950170-25-069251.md) | [32.7](/filings/0000950170-25-107352.md) | [33.3](/filings/0001193125-25-274303.md) | [34.8](/filings/0001193125-26-342373.md) | [29.7](/filings/0001193125-26-225841.md) | [26.2](/filings/0001193125-26-342373.md) |
| Shareholders' equity | $m | [(1,093)](/filings/0000950170-24-125312.md) | [(1,103)](/filings/0001193125-26-113881.md) | [(1,096)](/filings/0000950170-25-107352.md) | [(972)](/filings/0001193125-25-274303.md) | [(980)](/filings/0001193125-25-274303.md) | [(995)](/filings/0001193125-26-342373.md) | [(999)](/filings/0001193125-26-342373.md) | [(1,003)](/filings/0001193125-26-342373.md) | [(1,008)](/filings/0001193125-25-274303.md) | [(1,011)](/filings/0001193125-26-342373.md) | [(1,024)](/filings/0001193125-26-342373.md) | [(884)](/filings/0001193125-26-342373.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(23.8) d](/filings/0000950170-24-125312.md) | [(25.4) d](/filings/0001193125-26-113881.md) | [(34.6)](/filings/0000950170-25-069251.md) | [(38.3) d](/filings/0000950170-25-107352.md) | [(29.2) d](/filings/0001193125-25-274303.md) | [(24.2) d](/filings/0001193125-26-113881.md) | [(29.6)](/filings/0001193125-26-225841.md) | [(31.4) d](/filings/0001193125-26-342373.md) | [(26.6) d](/filings/0001193125-25-274303.md) | [(32.5) d](/filings/0001193125-26-113881.md) | [(41.7)](/filings/0001193125-26-225841.md) | [(40.4) d](/filings/0001193125-26-342373.md) |
| Capital expenditure | $m | [27.9 d](/filings/0000950170-24-125312.md) | [1.6 d](/filings/0001193125-26-113881.md) | [1.0](/filings/0000950170-25-069251.md) | [0.6 d](/filings/0000950170-25-107352.md) | [2.4 d](/filings/0001193125-25-274303.md) | [25.5 d](/filings/0001193125-26-113881.md) | [1.1](/filings/0001193125-26-225841.md) | [3.1 d](/filings/0001193125-26-342373.md) | [5.2 d](/filings/0001193125-25-274303.md) | [5.8 d](/filings/0001193125-26-113881.md) | [3.8](/filings/0001193125-26-225841.md) | [3.8 d](/filings/0001193125-26-342373.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.